Hybrid LNP Prime Dendritic Cells for Nucleotide Delivery.
TLR
cancer
dendritic cells
nanoparticles
vaccine stimulant
Journal
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
ISSN: 2198-3844
Titre abrégé: Adv Sci (Weinh)
Pays: Germany
ID NLM: 101664569
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
revised:
22
08
2023
received:
01
06
2023
medline:
27
11
2023
pubmed:
10
10
2023
entrez:
9
10
2023
Statut:
ppublish
Résumé
The efficient activation of professional antigen-presenting cells-such as dendritic cells (DC)-in tumors and lymph nodes is critical for the design of next-generation cancer vaccines and may be able to provide anti-tumor effects by itself through immune stimulation. The challenge is to stimulate these cells without causing excessive toxicity. It is hypothesized that a multi-pronged combinatorial approach to DC stimulation would allow dose reductions of innate immune receptor-stimulating TLR3 agonists while enhancing drug efficacy. Here, a hybrid lipid nanoparticle (LNP) platform is developed and tested for double-stranded RNA (polyinosinic:polycytidylic acid for TLR3 agonism) and immune modulator (L-CANDI) delivery. This study shows that the ≈120 nm hybrid nanoparticles-in-nanoparticles effectively eradicate tumors by themselves and generate long-lasting, durable anti-tumor immunity in mouse models.
Identifiants
pubmed: 37814359
doi: 10.1002/advs.202303576
pmc: PMC10667837
doi:
Substances chimiques
Toll-Like Receptor 3
0
Poly I-C
O84C90HH2L
Cancer Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2303576Subventions
Organisme : NCI NIH HHS
ID : R33 CA277820
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA079443
Pays : United States
Organisme : NCI NIH HHS
ID : R33CA277820
Pays : United States
Informations de copyright
© 2023 The Authors. Advanced Science published by Wiley-VCH GmbH.
Références
Front Immunol. 2017 Oct 30;8:1419
pubmed: 29163495
Gynecol Oncol. 1986 Jul;24(3):359-61
pubmed: 3721308
Commun Biol. 2021 Aug 11;4(1):956
pubmed: 34381159
Sci Transl Med. 2014 Apr 16;6(232):232ra51
pubmed: 24739759
J Am Chem Soc. 2012 Apr 25;134(16):6948-51
pubmed: 22475086
Clin Cancer Res. 2021 Sep 1;27(17):4781-4793
pubmed: 34233961
RSC Chem Biol. 2020 Jul 22;1(4):166-176
pubmed: 34458756
Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):1864-9
pubmed: 20080679
Cancer Discov. 2022 Jan;12(1):31-46
pubmed: 35022204
Chest. 2013 Jul;144(1):99-105
pubmed: 23348232
Immunol Res. 2021 Aug;69(4):312-322
pubmed: 34145551
Adv Drug Deliv Rev. 2021 Jun;173:70-88
pubmed: 33774114
Sci Immunol. 2023 May 12;8(83):eadd3955
pubmed: 37172103
ACS Infect Dis. 2019 Sep 13;5(9):1546-1558
pubmed: 31290323
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Clin Cancer Res. 2011 Mar 15;17(6):1603-15
pubmed: 21135147
Mol Ther. 2011 Dec;19(12):2186-200
pubmed: 21971424
Cell Chem Biol. 2020 Jan 16;27(1):94-104.e5
pubmed: 31902676
Clin Cancer Res. 2011 Jul 15;17(14):4844-53
pubmed: 21632857
Expert Rev Vaccines. 2011 Jun;10(6):733-42
pubmed: 21692696
Adv Mater. 2023 Feb;35(7):e2208782
pubmed: 36427266
Adv Sci (Weinh). 2023 Nov;10(33):e2303576
pubmed: 37814359
Pharmacol Ther. 2015 Feb;146:120-31
pubmed: 25281915
Clin Cancer Res. 2012 Dec 1;18(23):6497-508
pubmed: 23032745
Mol Ther. 2018 Jun 6;26(6):1509-1519
pubmed: 29653760
Nat Med. 2021 Mar;27(3):515-525
pubmed: 33479501
Immunity. 2010 Oct 29;33(4):492-503
pubmed: 21029960
Angew Chem Int Ed Engl. 2020 Apr 20;59(17):6839-6846
pubmed: 32004403
Mol Ther. 2016 Feb;24(1):146-55
pubmed: 26412590
Nano Lett. 2020 Jun 10;20(6):4543-4549
pubmed: 32375002
Immunity. 2016 Apr 19;44(4):924-38
pubmed: 27096321
Chembiochem. 2021 Feb 2;22(3):523-531
pubmed: 32909670
Nature. 2023 Jun;618(7963):144-150
pubmed: 37165196
Natl Cancer Inst Monogr. 1978 Dec;(49):325
pubmed: 372823
Nano Lett. 2015 Nov 11;15(11):7300-6
pubmed: 26469188
ACS Nano. 2018 May 22;12(5):4787-4795
pubmed: 29614232